Cell line/type | Glioma primary cells |
---|---|
Species | Human |
Animal free | No |
Product | UltraCULTUREā¢ Clavreulm et al. 2009 |
Clavreul, A., Jean, I., Preisser, L., Chassevent, A., Sapin, A., Michalak, S., & Menei, P. (2009). Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy. In Vitro Cellular & Developmental Biology-Animal, 45(9), 500-511. In this study, a medium containing human serum and one serum-free medium (UltraCulture), supplemented or not with epidermal growth factor, were tested on morphology, survival, DNA content and TAA expression of human glioma cell lines and glioma biopsy primary cultures. Their effects were compared on FCS-containing medium. Results show that, whatever the medium used, no significant variations in morphology and survival were observed. Furthermore, human serum-containing medium or UltraCulture preserved at early passage cultures the cell population of interest present in the biopsies before culture. In addition, the expression profile of eight TAAs was similar between these media. These data indicate that human serum-containing medium and UltraCulture serum-free medium could be promising candidates to produce tumour-cell vaccines. UltraCULTURE™ is a commercial product, and consists of a DMEM:F-12 base which is supplemented with recombinant human insulin, bovine transferrin and a purified mixture of bovine serum proteins including albumin. The formulation for UltraCULTURE™ Medium has been submitted to the FDA as a Master File. Permission to cross-reference the Master File may be obtained by contacting the Regulatory Affairs Department. https://link.springer.com/content/pdf/10.1007%2Fs11626-009-9215-4.pdf |
|
Source | Literature - modified commercial product |
Chemically defined > Unspecified | Unspecified |
Contains phenol red > Unspecified | Unspecified |
Antibiotics free > No | No |